BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Daiichi Sankyo readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Daiichi Sankyo's drugs run\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06417814-1980@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT06417814)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Investigate the Efficacy and Safety of Dato-DXd With or
  Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in 
 Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Ce
 ll Lung Cancer\nEstimated primary completion: 11 January 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06417814
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06271837-2164@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06271837)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study of T-DXd as Monotherapy or in Combination With Ant
 i-cancer Agents in Patients With Selected HER2-expressing Tumors\nEstimate
 d primary completion: 10 February 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06271837
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04482309-2164@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20270323
DTEND;VALUE=DATE:20270324
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT04482309)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2.\nStudy: A Phase 2 Study of T-
 DXd in Patients With Selected HER2 Expressing Tumors\nEstimated primary co
 mpletion: 23 March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04482309
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04145622-2527@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT04145622)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2.\nStudy: Study of Ifinatamab 
 Deruxtecan (DS-7300a\, I-DXd) in Participants With Advanced Solid Malignan
 t Tumors\nEstimated primary completion: 30 April 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04145622
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03793478-2836@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Quizartinib: Phase 1/2 readout est. (NCT03793478)
DESCRIPTION:Quizartinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Safet
 y and Efficacy of Quizartinib in Children and Young Adults With Acute Myel
 oid Leukemia (AML)\, a Cancer of the Blood\nEstimated primary completion: 
 1 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/quizartin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 3793478
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04784715-2164@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20270503
DTEND;VALUE=DATE:20270504
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT04784715)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3\, Breast Cancer.\nStudy: Trast
 uzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane\, Trast
 uzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-B
 reast09)\nEstimated primary completion: 3 May 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04784715
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04379596-2164@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT04379596)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2.\nStudy: Ph1b/2 Study of the S
 afety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastr
 ic Cancer (DESTINY-Gastric03)\nEstimated primary completion: 4 May 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT043
 79596
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04644068-1980@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Datopotamab Deruxtecan: Phase 1/2 readout est. (NCT04644068)
DESCRIPTION:Datopotamab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: Study of AZD5305 as Monotherapy and in Combination With Anti-can
 cer Agents in Patients With Advanced Solid Malignancies\nEstimated primary
  completion: 28 May 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/datopotamab-deruxtecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04644068
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405151-2527@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20270612
DTEND;VALUE=DATE:20270613
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT07405151)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Esophageal Squamous Cell Ca
 rcinoma.\nStudy: A Clinical Trial of Ifinatamab Deruxtecan in People With 
 Advanced Esophageal Cancer (MK-3475-06F)\nEstimated primary completion: 12
  June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ifinatama
 b-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07405151
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06362252-2527@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20270720
DTEND;VALUE=DATE:20270721
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT06362252)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Small Cell Lung Cancer.\nSt
 udy: A Study of I-DXd in Combination With Atezolizumab With or Without Car
 boplatin as First-Line Induction or Maintenance in Subjects With Extensive
  Stage-Small Cell Lung Cancer (IDeate-Lung03)\nEstimated primary completio
 n: 20 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ifin
 atamab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06362252
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06103864-1980@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20270728
DTEND;VALUE=DATE:20270729
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT06103864)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Breast Cancer.\nStudy: A Pha
 se III Study of Dato-DXd With or Without Durvalumab Compared With Investig
 ator's Choice of Chemotherapy in Combination With Pembrolizumab in Patient
 s With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-ne
 gative Breast Cancer (TROPION-Breast05)\nEstimated primary completion: 28 
 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/datopotama
 b-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06103864
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05629585-1980@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT05629585)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Breast Cancer.\nStudy: A Stu
 dy of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of 
 Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without
  Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Bre
 ast03)\nEstimated primary completion: 1 September 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05629585
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05489211-1980@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT05489211)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, Urothelial Carcinoma.\nStudy
 : Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Age
 nts in Patients With Advanced Solid Tumours (TROPION-PanTumor03)\nEstimate
 d primary completion: 1 October 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05489211
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05950945-2164@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT05950945)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormon
 e Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 M
 etastatic Breast Cancer\nEstimated primary completion: 1 October 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05950
 945
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05687266-1980@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT05687266)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Phase III\, Open-label\, First-line Study of Dato-DXd in Combinati
 on With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable G
 enomic Alterations\nEstimated primary completion: 1 November 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05687266
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07069712-2164@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20271109
DTEND;VALUE=DATE:20271110
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07069712)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2.\nStudy: A Study of Novel Agen
 ts or Combinations as Perioperative Treatment in Participants With Locally
  Advanced Resectable Gastroesophageal Adenocarcinoma\nEstimated primary co
 mpletion: 9 November 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07069712
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04471727-2527@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20280128
DTEND;VALUE=DATE:20280129
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT04471727)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Small Cell Lung Cancer.\nSt
 udy: A Study in Participants With Advanced Cancers Associated With Express
 ion of DLL3 (MK-6070-001/HPN328-4001)\nEstimated primary completion: 28 Ja
 nuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ifinatama
 b-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04471727
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06203210-2527@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Ifinatamab Deruxtecan: Phase 3 readout est. (NCT06203210)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 3\, Small Cell Lung Cancer.\nStud
 y: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice
  in Subjects With Relapsed Small Cell Lung Cancer\nEstimated primary compl
 etion: 30 January 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ifinatamab-deruxtecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06203210
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07205822-1980@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20280202
DTEND;VALUE=DATE:20280203
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT07205822)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study of Dato-DXd in Inoperable or Metastatic Hormone Re
 ceptor-positive\, HER2 IHC 0 Breast Cancer\nEstimated primary completion: 
 2 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dato
 potamab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07205822
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05417594-1980@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20280207
DTEND;VALUE=DATE:20280208
SUMMARY:Datopotamab Deruxtecan: Phase 1/2 readout est. (NCT05417594)
DESCRIPTION:Datopotamab Deruxtecan\, phase 1/2.\nStudy: Study of AZD9574 as
  Monotherapy and in Combination With Anti-cancer Agents in Participants Wi
 th Advanced Solid Malignancies\nEstimated primary completion: 7 February 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deru
 xtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05417594
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06174987-2164@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20280217
DTEND;VALUE=DATE:20280218
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT06174987)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3.\nStudy: A Study to Provide Co
 ntinued Access to and Assess Long-Term Safety of the Study Drug(s)\nEstima
 ted primary completion: 17 February 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06174987
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06161025-2696@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Raludotatug Deruxtecan: Phase 2/3 readout est. (NCT06161025)
DESCRIPTION:Raludotatug Deruxtecan\, phase 2/3.\nStudy: A Study of Raludota
 tug Deruxtecan (R-DXd) in Subjects With Platinum-resistant\, High-grade Ov
 arian\, Primary Peritoneal\, or Fallopian Tube Cancer\nEstimated primary c
 ompletion: 29 February 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/raludotatug-deruxtecan#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06161025
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06350097-1980@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT06350097)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Phase III\, Open-label Study of First-line Osimertinib With or Wit
 hout Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-s
 mall Cell Lung Cancer\nEstimated primary completion: 21 March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06350097
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06644768-2791@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Ezharmia (valemetostat tosylate): Phase 1/2 readout est. (NCT066447
 68)
DESCRIPTION:Ezharmia (valemetostat tosylate)\, phase 1/2\, Non-Small Cell L
 ung Cancer.\nStudy: A Study of Valemetostat Tosylate Plus Pembrolizumab Ve
 rsus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Al
 terations\nEstimated primary completion: 30 March 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/valemetostat-tosylate#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06644768
URL:https://assetmemo.bio/drug/valemetostat-tosylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06445972-1981@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20280509
DTEND;VALUE=DATE:20280510
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT06445972)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2.\nStudy: Substudy 06D: Combin
 ation Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-34
 75-06D/Keymaker-U06)\nEstimated primary completion: 9 May 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06445972
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731478-2164@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT06731478)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3.\nStudy: Study of TDXd\, Chemo
 therapy\, Pembrolizumab\, and Trastuzumab in First-Line Metastatic HER2-Po
 sitive Gastric or Gastroesophageal Junction Cancer\nEstimated primary comp
 letion: 1 June 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06731478
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06644781-2527@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Ifinatamab Deruxtecan: Phase 3 readout est. (NCT06644781)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 3\, Esophageal Squamous Cell Carc
 inoma.\nStudy: A Study of Ifinatamab Deruxtecan in Subjects With Pretreate
 d Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate
 -Esophageal01)\nEstimated primary completion: 1 June 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06644781
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06824168-2836@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:Quizartinib: Phase 2 readout est. (NCT06824168)
DESCRIPTION:Quizartinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Evaluat
 ion of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute
  Myeloid Leukemia Patients in Complete Remission\nEstimated primary comple
 tion: 6 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/qu
 izartinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06824168
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06467357-2164@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20280612
DTEND;VALUE=DATE:20280613
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT06467357)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3.\nStudy: Phase 3 Study of T-DX
 d and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract C
 ancer\nEstimated primary completion: 12 June 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06467357
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06925737-2527@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20280626
DTEND;VALUE=DATE:20280627
SUMMARY:Ifinatamab Deruxtecan: Phase 3 readout est. (NCT06925737)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 3.\nStudy: A Clinical Study of If
 inatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-
 2400-001)\nEstimated primary completion: 26 June 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06925737
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06330064-2527@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20280725
DTEND;VALUE=DATE:20280726
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT06330064)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2.\nStudy: A Study to Evaluate 
 the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With 
 Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)\nEstimated primar
 y completion: 25 July 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ifinatamab-deruxtecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06330064
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05875168-7685@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20280811
DTEND;VALUE=DATE:20280812
SUMMARY:DS-3939a: Phase 1/2 readout est. (NCT05875168)
DESCRIPTION:DS-3939a\, phase 1/2.\nStudy: First-in-Human Study of DS-3939a 
 in Participants With Advanced Solid Tumors\nEstimated primary completion: 
 11 August 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ds-39
 39a#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05875168
URL:https://assetmemo.bio/drug/ds-3939a#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06819007-2164@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT06819007)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3.\nStudy: Study of Trastuzumab 
 Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line 
 Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)\nEstimat
 ed primary completion: 1 November 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06819007
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06112379-1980@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20281120
DTEND;VALUE=DATE:20281121
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT06112379)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Breast Cancer.\nStudy: A Pha
 se III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvan
 t/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negat
 ive Breast Cancer\nEstimated primary completion: 20 November 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06112379
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06130553-1980@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20281204
DTEND;VALUE=DATE:20281205
SUMMARY:Datopotamab Deruxtecan: Phase 1/2 readout est. (NCT06130553)
DESCRIPTION:Datopotamab Deruxtecan\, phase 1/2.\nStudy: A Study of AZD3470\
 , a PRMT5 Inhibitor\, Given as Monotherapy and in Combination in Patients 
 With MTAP Deficient Advanced/Metastatic Solid Tumors\nEstimated primary co
 mpletion: 4 December 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/datopotamab-deruxtecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06130553
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06596694-1981@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20281207
DTEND;VALUE=DATE:20281208
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT06596694)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2.\nStudy: Study of Patritumab 
 Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HE
 RTHENA-PanTumor02)\nEstimated primary completion: 7 December 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06596694
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07941609-1980@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20281216
DTEND;VALUE=DATE:20281217
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT07941609)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Investigate the Efficacy and Safety of Dato-DXd-based C
 ombinations in Participants With TROP2 NMR+ NSCLC\nEstimated primary compl
 etion: 16 December 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/datopotamab-deruxtecan#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07941609
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06989112-2164@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20290119
DTEND;VALUE=DATE:20290120
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT06989112)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3.\nStudy: DESTINY-Endometrial01
 : A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembro
 lizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+)\, Mismatch 
 Repair Proficient (pMMR) Endometrial Cancer\nEstimated primary completion:
  19 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tra
 stuzumab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06989112
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07291037-1980@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20290129
DTEND;VALUE=DATE:20290130
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT07291037)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Prev
 iously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Wi
 thout Actionable Genomic Alterations\nEstimated primary completion: 29 Jan
 uary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/datopotama
 b-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07291037
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780137-2527@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20290215
DTEND;VALUE=DATE:20290216
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT06780137)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Small Cell Lung Cancer.\nSt
 udy: A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) an
 d Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory E
 xtensive-Stage Small Cell Lung Cancer (MK-6070-002)\nEstimated primary com
 pletion: 15 February 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ifinatamab-deruxtecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06780137
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06843447-2696@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20290327
DTEND;VALUE=DATE:20290328
SUMMARY:Raludotatug Deruxtecan: Phase 1/2 readout est. (NCT06843447)
DESCRIPTION:Raludotatug Deruxtecan\, phase 1/2\, Ovarian Cancer.\nStudy: A 
 Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK
 -5909-003).\nEstimated primary completion: 27 March 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06843447
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07098338-1980@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20290406
DTEND;VALUE=DATE:20290407
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT07098338)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC
 )\nEstimated primary completion: 6 April 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07098338
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764875-2164@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20290427
DTEND;VALUE=DATE:20290428
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT06764875)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3.\nStudy: A Phase Ⅲ Study of 
 Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxte
 can as the First-line Treatment for HER2-positive Gastric Cancer\nEstimate
 d primary completion: 27 April 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06764875
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05555732-1980@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20290511
DTEND;VALUE=DATE:20290512
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT05555732)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Withou
 t Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)\
 nEstimated primary completion: 11 May 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05555732
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07129993-1980@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Datopotamab Deruxtecan: Phase 2/3 readout est. (NCT07129993)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2/3\, Urothelial Carcinoma.\nStu
 dy: Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus G
 emcitabine Plus Carboplatin or Cisplatin in Participants With Locally Adva
 nced or Metastatic Urothelial Carcinoma\nEstimated primary completion: 1 J
 une 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/datopotamab
 -deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07129993
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07791732-2696@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Raludotatug Deruxtecan: Phase 3 readout est. (NCT07791732)
DESCRIPTION:Raludotatug Deruxtecan\, phase 3\, Ovarian Cancer.\nStudy: A St
 udy of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maint
 enance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer 
 (REJOICE-Ovarian03)\nEstimated primary completion: 1 July 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07791732
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286149-1981@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20290817
DTEND;VALUE=DATE:20290818
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT07286149)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer.
 \nStudy: A Clinical Study of MK-1084 With Other Treatments for Non-small C
 ell Lung Cancer (MK-3475-01F)\nEstimated primary completion: 17 August 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxte
 can#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07286149
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06469944-1981@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20290912
DTEND;VALUE=DATE:20290913
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT06469944)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2.\nStudy: Substudy 06C: A Stud
 y of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy 
 in Participants With First-Line Locally Advanced Unresectable/Metastatic G
 astroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)\nEstimated prima
 ry completion: 12 September 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/patritumab-deruxtecan#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06469944
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890714-1980@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Datopotamab Deruxtecan: Phase 1/2 readout est. (NCT07890714)
DESCRIPTION:Datopotamab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: A Study of Dato-DXd in Participants With Solid Tumors [TROPION-P
 anTumor04 (TP04)]\nEstimated primary completion: 30 September 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07890714
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04938817-2696@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20291210
DTEND;VALUE=DATE:20291211
SUMMARY:Raludotatug Deruxtecan: Phase 1/2 readout est. (NCT04938817)
DESCRIPTION:Raludotatug Deruxtecan\, phase 1/2.\nStudy: Safety and Efficacy
  Study of Investigational Agents as Monotherapy or in Combination With Pem
 brolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung 
 Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)\
 nEstimated primary completion: 10 December 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04938817
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06357533-1980@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20291228
DTEND;VALUE=DATE:20291229
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT06357533)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Phase III\, Open-label\, Study of First-line Dato-DXd in Combinati
 on With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expr
 ession (TC ≥ 50%) and Without Actionable Genomic Alterations\nEstimated 
 primary completion: 28 December 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06357533
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06660654-2696@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Raludotatug Deruxtecan: Phase 2 readout est. (NCT06660654)
DESCRIPTION:Raludotatug Deruxtecan\, phase 2.\nStudy: A Study of Raludotatu
 g Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOIC
 E-PanTumor01)\nEstimated primary completion: 30 December 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06660654
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797635-1981@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Patritumab Deruxtecan: Phase 2 readout est. (NCT06797635)
DESCRIPTION:Patritumab Deruxtecan\, phase 2\, Breast Cancer.\nStudy: Study 
 of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents i
 n Participants With High-Risk Early-Stage Triple-Negative or Hormone Recep
 tor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010\, HERTHENA-Brea
 st-03)\nEstimated primary completion: 31 December 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06797635
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07022483-2164@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20300226
DTEND;VALUE=DATE:20300227
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT07022483)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3.\nStudy: A Study of Trastuzuma
 b Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC
  3+/2+) Endometrial Cancer in Adjuvant Setting\nEstimated primary completi
 on: 26 February 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07022483
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05215340-1980@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20300304
DTEND;VALUE=DATE:20300305
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT05215340)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the
  First-line Treatment of Subjects With Advanced or Metastatic NSCLC Withou
 t Actionable Genomic Alterations\nEstimated primary completion: 4 March 20
 30. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/datopotamab-derux
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05215340
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06899126-2164@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20300424
DTEND;VALUE=DATE:20300425
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT06899126)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Study of Trastuzumab Deruxtecan\, Pembrolizumab\, and Platinum-bas
 ed Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Canc
 er\nEstimated primary completion: 24 April 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06899126
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05061550-1980@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20300528
DTEND;VALUE=DATE:20300529
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT05061550)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lu
 ng Cancer\nEstimated primary completion: 28 May 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05061550
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06578247-2836@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20300626
DTEND;VALUE=DATE:20300627
SUMMARY:Quizartinib: Phase 3 readout est. (NCT06578247)
DESCRIPTION:Quizartinib\, phase 3\, Acute Myeloid Leukemia.\nStudy: Quizart
 inib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-IT
 D Negative AML\nEstimated primary completion: 26 June 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/quizartinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06578247
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683754-2164@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20300704
DTEND;VALUE=DATE:20300705
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT07683754)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: T-DXd Based Therapy Followed by Endocrine Therapy Plus Dua
 l HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retr
 eatment With T-DXd\nEstimated primary completion: 4 July 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07683754
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739966-7685@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:DS-3939a: Phase 1/2 readout est. (NCT07739966)
DESCRIPTION:DS-3939a\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of DS-3939a in Participants With Solid Tumors\nEstimated primary compl
 etion: 31 July 2030. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ds-3939a#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07739966
URL:https://assetmemo.bio/drug/ds-3939a#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720284-1980@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20300911
DTEND;VALUE=DATE:20300912
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT07720284)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Urothelial Carcinoma.\nStudy
 : An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd +
  Rilvegostomig vs SoC in Adult Participants With High-risk MIUC\nEstimated
  primary completion: 11 September 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07720284
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06172478-1981@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20301119
DTEND;VALUE=DATE:20301120
SUMMARY:Patritumab Deruxtecan: Phase 2 readout est. (NCT06172478)
DESCRIPTION:Patritumab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic
  Solid Tumors\nEstimated primary completion: 19 November 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06172478
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227597-2527@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20301129
DTEND;VALUE=DATE:20301130
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT07227597)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Small Cell Lung Cancer.\nSt
 udy: A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (M
 K-2400) in People With Small Cell Lung Cancer (MK-6070-003)\nEstimated pri
 mary completion: 29 November 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ifinatamab-deruxtecan#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07227597
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06941272-1981@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT06941272)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2.\nStudy: A Study of Patrituma
 b Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid T
 umors (MK-9999-01C/LIGHTBEAM-U01)\nEstimated primary completion: 30 Decemb
 er 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/patritumab-d
 eruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06941272
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07701941-1981@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20310101
DTEND;VALUE=DATE:20310102
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT07701941)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study of Patritumab Deruxtecan (HER3-DXd) in Combinatio
 n With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive\, H
 ER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer\nEstimat
 ed primary completion: 1 January 2031. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/patritumab-deruxtecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07701941
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07630974-2527@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20310817
DTEND;VALUE=DATE:20310818
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT07630974)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2.\nStudy: A Study of Ifinatama
 b Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid T
 umors (MK-9999-01D/LIGHTBEAM-U01)\nEstimated primary completion: 17 August
  2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/ifinatamab-der
 uxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07630974
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743164-2696@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Raludotatug Deruxtecan: Phase 3 readout est. (NCT07743164)
DESCRIPTION:Raludotatug Deruxtecan\, phase 3\, Ovarian Cancer.\nStudy: A Cl
 inical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab
  in Participants With Ovarian Cancer Who Have Progressed During Treatment 
 With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGO
 T-ov107/GOG-3142 / REJOICE-Ovarian05)\nEstimated primary completion: 31 Au
 gust 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/raludotatu
 g-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07743164
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06863272-2527@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20311001
DTEND;VALUE=DATE:20311002
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT06863272)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2.\nStudy: A Clinical Study of 
 Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Tr
 eat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDe
 ate-Prostate02)\nEstimated primary completion: 1 October 2031. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06863272
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780111-2527@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20320104
DTEND;VALUE=DATE:20320105
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT06780111)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Esophageal Squamous Cell Ca
 rcinoma.\nStudy: Substudy 06E: Umbrella Study of Combination Therapies in 
 Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)\nEstimated primary completion
 : 4 January 2032. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ifi
 natamab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06780111
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04165070-1981@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20320213
DTEND;VALUE=DATE:20320214
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT04165070)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer.
 \nStudy: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembroliz
 umab (MK-3475) With or Without Chemotherapy When Used With Investigational
  Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung
  Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)\nEstimated primary completion:
  13 February 2032. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pa
 tritumab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04165070
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780098-2527@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20320302
DTEND;VALUE=DATE:20320303
SUMMARY:Ifinatamab Deruxtecan: Phase 2 readout est. (NCT06780098)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Substudy 01I: A Study of Investigational Agents in Participants Wit
 h Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) 
 (MK-3475-01I/KEYMAKER-U01I)\nEstimated primary completion: 2 March 2032. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ifinatamab-deruxtecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0678
 0098
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780085-2527@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20320312
DTEND;VALUE=DATE:20320313
SUMMARY:Ifinatamab Deruxtecan: Phase 2 readout est. (NCT06780085)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of Investigational Agents in Participants With Previously T
 reated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01
 H/KEYMAKER-U01)\nEstimated primary completion: 12 March 2032. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06780085
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731907-1981@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20320312
DTEND;VALUE=DATE:20320313
SUMMARY:Patritumab Deruxtecan: Phase 2 readout est. (NCT06731907)
DESCRIPTION:Patritumab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of Pembrolizumab With or Without Chemotherapy in Combinatio
 n With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCL
 C) (MK-3475-01G/KEYMAKER U01)\nEstimated primary completion: 12 March 2032
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxtec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6731907
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776691-2696@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20320319
DTEND;VALUE=DATE:20320320
SUMMARY:Raludotatug Deruxtecan: Phase 3 readout est. (NCT07776691)
DESCRIPTION:Raludotatug Deruxtecan\, phase 3\, Ovarian Cancer.\nStudy: A St
 udy of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Ma
 intenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-0
 06\, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)\nEstimated primary complet
 ion: 19 March 2032. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/r
 aludotatug-deruxtecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07776691
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06686394-1981@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20320802
DTEND;VALUE=DATE:20320803
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT06686394)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2\, Breast Cancer.\nStudy: Stud
 y of Patritumab Deruxtecan With Other Anticancer Agents in Participants Wi
 th HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Re
 moved (MK-1022-009)\nEstimated primary completion: 2 August 2032. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06686394
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07060807-1981@assetmemo.bio
DTSTAMP:20261121T005703Z
DTSTART;VALUE=DATE:20330714
DTEND;VALUE=DATE:20330715
SUMMARY:Patritumab Deruxtecan: Phase 3 readout est. (NCT07060807)
DESCRIPTION:Patritumab Deruxtecan\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Clinical Study of Patritumab Deruxtecan to Treat Breast C
 ancer (MK-1022-016)\nEstimated primary completion: 14 July 2033. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07060807
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
